1. Department: HBC

Today’s Rare Disease Launches Require the Right Specialty Pharmacy Partner

Written by Posted on Less than 0 min read

Today’s guest post comes from Richard Faris, Chief Strategy & Growth Officer at PANTHERx Rare Pharmacy.

Richard outlines the key factors for commercialization success when a manufacturer launches treatments for rare and orphan diseases. He explains the key considerations for choosing a specialty pharmacy network design, selecting the right pharmacy partners, and establishing patient services HUBs.

To learn more, download PANTHERx’s latest white paper and SP decision-support resource: Selecting the Right Specialty Pharmacy Partner for a Successful Launch.

Read on for Richard’s insights.

Read more »

© 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Post Views: 95
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Data & Insights

Hubs: The Bridge Between Patients and Providers

Today’s guest post comes from Josh Marsh, Vice President and General Manager, Sonexus™ Access and Patient Support at Cardinal Health. Josh examines the central role that hubs play in connecting patients, providers, and other stakeholders. He shares how hubs, by gathering and interpreting real-world insights, can help improve access, adherence, and the overall patient experience. […]
2 min read
0
  1. Corporate Strategy

Addressing Gaps in Access: Strategies to Optimize Your Prescription Journey

Today’s guest post comes from Catherine Wood Hill, SVP of Marketing at PHIL. Catherine reviews the prescription lifecycle from the perspectives of patients, providers, and manufacturers. She explains how manufacturers can support patients with clear comunication about their prescriptions. Catherine then outlines five strategies to help providers have more informed conversations with patients. To learn […]
2 min read
0
  1. Media & Marketing

Three Areas to Watch: The Inflation Reduction Act and Prescription Pricing

Today’s guest post comes from H. John Beardsley, Senior Vice President of Corporate Strategy at CoverMyMeds John discusses how the new maximum fair prices (MFPs) published by the Centers for Medicaid & Medicare Services (CMS) will affect medication affordability, formulary negotiations, evidence-based strategies, and other aspects of the market. To learn more, register for CoverMyMeds’ […]
2 min read
0
  1. Trends & External Forces

NEW: The Drug Channels 2026 Video Webinar Series

Join Dr. Adam J. Fein, president of Drug Channels Institute (DCI), for three new video webinars during 2026. These live, interactive events are designed for executives who need timely insight into the rapidly changing U.S. drug channel. They will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia. Register Now […]
4 min read
0
  1. Department: HBC

As Pharma Faces Financial Pressure, Pharmacy Delivers Measurable Impact

Today’s guest post comes from Lara Loveman, VP of Pharma Solutions at Outcomes. Lara discusses how shifting market forces and evolving reimbursement models are reshaping pharmaceutical marketing strategies. She suggests that pharmacist-led interventions—particularly in chronic disease management—can both protect pharmaceutical investment and drive better health outcomes. Click here to learn about Outcomes’ pharmacist-led interventions solution. […]
2 min read
0
  1. Media & Marketing

Drug Channels Leadership Forum: Full Agenda Now Available (Spoiler: It’s Awesome!)

I am pleased to announce the full agenda for the inaugural Drug Channels Leadership Forum, which will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. Everyone here at Drug Channels Institute (DCI) is excited to bring this novel event to the drug channels community. I personally assembled […]
3 min read
0
  1. Department: Food

Drug Channels News Roundup, September 2024: Inside JNJ’s Gross-to-Net Bubble, Optum Rx’s Private Label Biosimilars, Where Biosimilars Boom, Accumulators vs. Patients, and Steve Collis Retires

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these acorns that we’ve squirrelled away for you: Johnson & Johnson Innovative Medicines gives a peek inside its $43 billion gross-to-net bubble Optum Rx joins the private label biosimilar bandwagon Biosimilars boom for provider-administered drugs Fresh evidence of how copay accumulators hurt patients […]
2 min read
0
  1. Media & Marketing

How Large PBMs Make Money Today: A 2025 Drug Channels Update

During my PBM Industry Update: Trends, Challenges, and What’s Ahead video webinar, I explored the latest trends, emerging data, and strategic shifts transforming the pharmacy benefit management (PBM) industry. In the video clip below, I explain how PBM compensation models continue to evolve: Traditional profit sources, such as mail dispensing of nonspecialty drugs and retained […]
2 min read
0
  1. Data & Insights

Informa Connect’s Trade and Channel Strategies

Informa Connect’s Trade and Channel Strategies December 9-11, 2025 | W Philadelphia Exclusive Offer—Use promo 25DC10 to save 10%* The stakes have never been higher. With seismic shifts in distribution models, health policy and market access strategies, falling behind on critical trends could mean losing your competitive edge. If you’re a trade, channel, market access […]
3 min read
0
  1. Trends & External Forces

Inflation-Adjusted U.S. Brand-Name Drug Prices Fell for the Seventh Consecutive Year as a New Era of Drug Pricing Dawns (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: PBM Industry Update: Trends, Challenges, and What’s Ahead. Click here to see the original post from January 2025. It’s time for Drug Channels’ annual examination of U.S. brand-name drug pricing. For 2024, average brand-name drugs’ list prices grew by only […]
3 min read
0
  1. Trends & External Forces

Drug Channels Leadership Forum 2026: Request an Invitation Before It’s Too Late!

The 2026 Drug Channels Leadership Forum (DCLF) is coming soon! Our second annual event will take place March 16–18, 2026, at the Turnberry Resort & Spa in Miami. Once again, Drug Channels Institute (DCI) is proud to host this invite-only gathering of senior leaders across the drug channel ecosystem. You must request an invitation to […]
3 min read
0
  1. Data & Insights

Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different

Today’s guest post is from Dr. Richard Faris, Chief Commercial and Clinical Officer at PANTHERx Rare. Richard examines key considerations in launching rare disease therapies. He  argues that targeted reach, tighter relationships, and data-driven collaboration can improve success for both patients and manufacturers. To learn more, download PANTHERx Rare’s free guide: From PDUFA to Patient: A […]
2 min read
0
  1. Trends & External Forces

Informa Connect’s Copay, Reimbursement and Access Congress 2025

Informa Connect’s Copay, Reimbursement and Access Congress 2025 November 18-20, 2025 | Hilton New Brunswick, East Brunswick, NJ Exclusive Offer–Use promo USAVE25 to save 10%* on your registration The healthcare landscape continues to evolve at an unprecedented pace, bringing new challenges and opportunities for patient access and affordability. As legislation shifts, market forces disrupt and […]
3 min read
0
  1. Data & Insights

Rewriting the Access Script: A Pharmacist’s View on the Rise of Direct-to-Patient

Today’s guest post comes from Lindsay Reel, VP of Pharmacy Practice & Specialty Solutions at EVERSANA. In this article, Lindsay shares a pharmacist’s firsthand perspective on the growing complexity of patient access and the limitations of traditional pharmacy models. She argues that emerging Direct-to-Patient (DTP) strategies can reshape the care experience by addressing longstanding inefficiencies, […]
2 min read
0
  1. Data & Insights

White Bagging Update 2024: Providers’ Pushback Preserves Buy-and-Bill

Time for DCI’s annual update on the channels for provider-administered drugs. Below, I review the latest data on 2024 trends and compare them to the pre-pandemic figures. For 2024, payers report that specialty pharmacies—via white and clear bagging—have displaced buy-and-bill for a meaningful share of commercial covered lives utilizing provider-administered oncology drugs. However, provider pushback […]
2 min read
0
  1. Trends & External Forces

Drug Channels News Roundup, May 2025: MFN Controversy, Plan Sponsors ♥️ Rebates, PBM Profits, and Fun in Congress

Summer unofficially began over the weekend. To mark the occasion, here are a few hot items, freshly seared on the Drug Channels grill: Reactions from the Drug Channels community to the Most Favored Nation (MFN) pricing policy A reality check on whether plan sponsors truly want rebate reform What plan sponsors should know about the […]
2 min read
0
  1. Trends & External Forces

2024 Gross-to-Net Realities at 9 Top Drugmakers: A New Era of Market Access (rerun)

This week, I’m rerunning some popular posts while I put the finishing touches on DCI’s 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from July 2025. It’s time for Drug Channels’ annual update on drug pricing trends at the largest pharmaceutical manufacturers. This year’s review includes the […]
3 min read
0
  1. Media & Marketing

Reflections and Photos from the Inaugural Drug Channels Leadership Forum 2025

Wow! What an absolutely incredible time at the inaugural Drug Channels Leadership Forum (DCLF)! Paula and I are beyond grateful to everyone who took the stage to share their insights and to all who participated in making this event so impactful. (Even Paula got on the main stage!) The event was packed with thought-provoking discussions, […]
3 min read
0
  1. Media & Marketing

340B Hit $81 Billion in 2024: Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth (VIDEO)

Yesterday, I published 340B Hit $81 Billion in 2024 (+23%): Why CMS and the IRA Are Poised to Cool the Program’s Runaway Growth. For those who prefer watching to reading, I asked AI to turn our latest 340B analysis into a tidy little video. Let me know what you think of this format and whether […]
2 min read
0
  1. Data & Insights

Beyond Throughput: Building Reverification Strategies That Safeguard Access

Today’s guest post comes from Gregory Morris, Chief Strategy Officer at CareMetx. Gregory examines how Annual Reverification (AR) processes must evolve in response to changing payer dynamics and increasing benefit complexity. Rather than focusing solely on throughput and operational efficiency, he argues for the importance of more nuanced strategies that help ensure patients maintain access […]
2 min read
0
Next